bemarituzumab

News

Amgen's Five Prime takeover delivers gastric cancer win

Four years after buying Five Prime for $1.9bn, Amgen has promising phase 3 results with a gastric cancer drug that was the focal point for the deal.

News

Five Prime eyes financing after positive results with stomac...

Shares in US biotech Five Prime Therapeutics more than tripled after it reported promising trial results with stomach cancer drug candidate bemarituzumab, returning the stock to levels not

News

Sandoz adds 10 biosimilars through $322m Henlius deal

Sandoz is set to add up to 10 new biosimilar assets to its portfolio under a new collaboration deal with China’s Shanghai Henlius Biotech.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks